Aldeyra Therapeutics, INC. (ALDX) — 10-Q Filings

10-Q Filings (6)

• Aldeyra Narrows Q3 Loss by 49% on Steep R&D Cuts — Nov 5, 2025 Risk: medium
  Aldeyra Therapeutics, Inc. reported a net loss of $7,688,341 for the three months ended September 30, 2025, a significant improvement from the $15,112,983 net l
• Aldeyra Narrows Q2 Loss to $20.1M Amid Reproxalap Review — Aug 7, 2025 Risk: high
  Aldeyra Therapeutics, Inc. reported no revenue for the three and six months ended June 30, 2025, consistent with its prior-year periods, as it remains a clinica
• Aldeyra Therapeutics Files Q1 2025 10-Q — May 14, 2025 Risk: medium
  Aldeyra Therapeutics, Inc. filed a 10-Q for the period ending March 31, 2025. The company reported financial data related to its common stock and investments in
• Aldeyra Therapeutics Files Q3 2024 10-Q — Nov 7, 2024 Risk: medium
  Aldeyra Therapeutics, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported its financial results and provided updates on its busin
• Aldeyra Therapeutics Files Q2 2024 10-Q — Aug 1, 2024 Risk: medium
  Aldeyra Therapeutics, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported its financial results and provided updates on its business o
• Aldeyra Therapeutics Files 10-Q for Period Ending March 31, 2024 — May 2, 2024 Risk: medium
  Aldeyra Therapeutics, Inc. (ALDX) filed a Quarterly Report (10-Q) with the SEC on May 2, 2024. Aldeyra Therapeutics, Inc. filed a 10-Q report for the period end

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX